1.	Firmagon (Degarelix) Intermittent Therapy Phase: Phase IV Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: CURC - FIT-0002, NCT01512472
2.	Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000701128, RTOG-0924, NCT01368588
3.	One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 000006, NCT01744366
4.	A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: J1265, NA_00073453, NCT01696877
5.	S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000696565, S1014, U10CA032102, SWOG-S1014, NCT01309672
6.	Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0378, NCT01377389
7.	Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Phase: Phase II Type: Treatment Status: Active Age: 40 to 80 Sponsor: Other Protocol IDs: H11-08172, NCT01446991
8.	Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC) Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: BCCA_Deg01, NCT01630967
9.	Degarelix Neo-Adjuvant Radical Prostatectomy Trial Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: DEG_PRE-OP_001, Degarelix Pre-Op, NCT01674270
10.	3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-187, NCT01751451
11.	Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2012-0993, NCT01786265
12.	Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CMX-DELAY2010, NCT01366053
13.	Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-182, NCT01542021
14.	Treatment of Prostate Cancer With Firmagon® Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: 18 to 95 Sponsor: Other Protocol IDs: UCM12-01, NCT01710098
15.	Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7846, NCI-2012-02136, P30CA015704, NCT01731912